AdvanCell Strengthens Executive Leadership to Accelerate U.S. Expansion and Scale its Global Targeted Alpha Therapy Platform
Justyna Kelly, MSc, joins as Chief Technology Officer and François Gaudet, PhD, joins as Chief…
AdvanCell Admin8 June 2026
Dr. Oliver Sartor interviews AdvanCell CMO Dr. Anna Karmann on TheraPb Phase 2 for UroToday
Anna Karmann outlines AdvanCell's Lead-212 alpha-emitting radioligand therapy program, covering the phase one experience and…
Presentation of the Novel Study Design for the Phase 2 Expansion Study of 212Pb-ADVC001 in Metastatic Prostate Cancer: The TheraPb Trial
Presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) 2026 on…
AdvanCell Admin27 February 2026
AdvanCell Showcases Novel TheraPb Phase 2 Study Design of ADVC001 for the Treatment of Metastatic Prostate Cancer at ASCO GU Symposium 2026
-- The trial uses a response-driven dosing strategy and extended treatment across three prostate cancer…
AdvanCell Admin24 February 2026
AdvanCell Announces Upcoming Presentation of TheraPb Phase 2 Expansion Study Design at ASCO Genitourinary Cancers Symposium 2026
Sydney, Australia and Boston, USA – January 22, 2026 – AdvanCell, a clinical-stage radiopharmaceutical company…
AdvanCell Admin22 January 2026
AdvanCell Appoints Philina Lee, PhD as Chief Executive Officer to Lead US Expansion and Drive Global Growth
Dr Lee is a seasoned biopharmaceutical executive with a proven track record of leading cross-functional…
AdvanCell Admin17 November 2025
TheraPb Phase 1b results featured by Urology Times in an interview with Principal investigator Aaron Hansen
Listen to the interview here: Aaron Hansen, MD, shares key findings from the theraPb trial…
AdvanCell Admin14 November 2025
AdvanCell featured as Emerging Company by BioCentury
Read the full article here: AdvanCell: Scaling up lead-212 production, keeping down tox
AdvanCell Admin13 November 2025
AdvanCell to participate in Jefferies Global Healthcare Conference in London
Sydney, Australia – 11 November 2025 – AdvanCell, a clinical-stage radiopharmaceutical company developing innovative…
AdvanCell Admin11 November 2025
AdvanCell’s 212Pb-ADVC001 demonstrates encouraging safety and compelling anti-tumor activity in Phase 1b in prostate cancer
Results from the TheraPb Phase 1b dose escalation presented at ESMO 2025 show a promising…
AdvanCell Admin18 October 2025
